The North American market for MASH treatments reached US$3.70 billion in 2024 and is projected to grow impressively at a 19.3% CAGR, hitting US$17.15 billion by 2033, buoyed by rising obesity, Type 2 diabetes, and increasing disease awareness https://www.datamintelligence.com/research-report/north-america-metabolic-dysfunction-associated-steatohepatitis-treatment-market